Fluticasone Furoate

證據等級: L5

預測適應症: 8 個

Fluticasone Furoate: From Undocumented Original Indication to Atopic Eczema

One-Sentence Summary

Fluticasone furoate is a corticosteroid whose original approved indication and mechanism of action are not documented in the current evidence pack, and it is currently not marketed in Germany (0 licenses on record). The TxGNN model predicts it may be effective for atopic eczema, but the supporting evidence base (9 clinical trials, 2 publications) tests the related compound fluticasone propionate rather than furoate itself.

Quick Overview

Item	Content
Original Indication	Not documented in current dataset (no license records available)
Predicted New Indication	Atopic eczema
TxGNN Prediction Score	99.98%
Evidence Level	L3
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (original_moa: Data Gap). Based on the information that is available, fluticasone furoate belongs to the corticosteroid (glucocorticoid) class and is described as a second-generation inhaled/intranasal corticosteroid, mechanistically related to fluticasone propionate. Both compounds act via glucocorticoid receptor activation, suppressing inflammatory mediators (IL-4, IL-13, TNF-α) — a pathway plausibly relevant to the skin-barrier inflammation seen in atopic eczema.

This pack does not record fluticasone furoate's currently approved indication or any German marketing history, so a direct "original → new indication" comparison cannot be made from the available data. Critically, essentially all of the supporting clinical evidence below tests topical fluticasone propionate cream/ointment formulations, not furoate. Furoate is currently only known to exist in nasal-spray and dry-powder inhaler formulations; no topical dermatologic formulation of furoate exists in the evidence provided. The prediction is therefore best characterized as a class-level (propionate-derived) inference, not molecule-specific evidence — and would additionally require new formulation development before any topical use in eczema could be considered.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00616538	Phase 4	Completed	121	Compared EpiCeram (non-steroidal barrier cream) vs. fluticasone propionate 0.05% cream in pediatric moderate-to-severe AD
NCT01772056	Phase 3	Terminated	54	Twice-weekly fluticasone propionate 0.05% cream maintenance therapy to reduce AD relapse in children
NCT00546000	Phase 4	Completed	56	Open-label study of Cutivate (fluticasone propionate) lotion 0.05% and effect on HPA axis in pediatric AD
NCT01915914	Phase 4	Completed	107	Intermittent fluticasone propionate 0.05% cream (2x/week) + moisturizer vs. moisturizer alone to reduce relapse in stabilized pediatric AD
NCT00689832	Phase 4	Completed	487	Tacrolimus 0.03% vs. fluticasone 0.005% ointment in children ≥2y with moderate-severe AD
NCT03742414	Phase 2	Active, not recruiting	398	Proactive skin-barrier care plus proactive fluticasone propionate cream vs. reactive therapy to prevent AD progression and food allergy
NCT07537751	N/A	Completed	40	Crisaborole 2% vs. fluticasone propionate 0.05% in children (1–12y) with mild-moderate AD
NCT00690105	Phase 4	Completed	577	Tacrolimus 0.1% vs. fluticasone 0.005% ointment in adults with facial ("red face") AD
NCT00119158	Phase 4	Completed	90	Pimecrolimus 1% + fluticasone (Cutivate) 0.05% combination vs. vehicle in severe AD lesions

Note: All trials above use fluticasone propionate formulations; none directly test fluticasone furoate in atopic eczema/dermatitis.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
19571596	2009	Review/Cohort	Neuroimmunomodulation	Reviews HPA-axis suppression risk from intranasal corticosteroids in allergic disease, noting frequent comorbidity with atopic dermatitis
40066386	2025	Case Study	Indian J Otolaryngol Head Neck Surg	Case report on allergen immunotherapy, mentioning atopic dermatitis as one of its emerging applications (background context only)

Germany Market Information

No marketing authorization is currently registered for fluticasone furoate in Germany (0 licenses on record; market status: not marketed).

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are not currently available in this evidence pack — flagged as a Blocking data gap, DG001.)

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for the atopic eczema prediction is class-level only (derived from fluticasone propionate trials, not furoate itself), furoate has no known topical dermatologic formulation, and the drug is not currently marketed in Germany. Combined with a blocking gap in safety/label data, there is insufficient basis to advance beyond a research question at this time.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain official German label warnings/contraindications before any S1 safety assessment
Resolve DG002: obtain documented mechanism of action and confirmed original approved indication(s) for fluticasone furoate
Furoate-specific (not propionate) clinical evidence in an eczema/dermatitis population
Formulation feasibility assessment — furoate currently exists only as nasal/inhaled products; a topical form would need to be developed
Consider evaluating the higher-evidence candidate identified elsewhere in this evidence pack: bronchitis (rank 2, L2, "Proceed with Guardrails"), which has direct furoate trial support (e.g., NCT02989935, RELVAR/fluticasone furoate-vilanterol in COPD/bronchitis)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.